PortalPublikationenHeart failure therapy-induced early ST2 changes may offer lo...

Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance

Standard

Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. / Breidthardt, Tobias; Balmelli, Cathrin; Twerenbold, Raphael; Mosimann, Tamina; Espinola, Jaqueline; Haaf, Philip; Thalmann, Gregor; Moehring, Berit; Mueller, Mira; Meller, Bernadette; Reichlin, Tobias; Murray, Karsten; Ziller, Ronny; Benkert, Pascal; Osswald, Stefan; Mueller, Christian.

in: J CARD FAIL, Jahrgang 19, Nr. 12, 12.2013, S. 821-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Breidthardt, T, Balmelli, C, Twerenbold, R, Mosimann, T, Espinola, J, Haaf, P, Thalmann, G, Moehring, B, Mueller, M, Meller, B, Reichlin, T, Murray, K, Ziller, R, Benkert, P, Osswald, S & Mueller, C 2013, 'Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance', J CARD FAIL, Jg. 19, Nr. 12, S. 821-8. https://doi.org/10.1016/j.cardfail.2013.11.003

APA

Breidthardt, T., Balmelli, C., Twerenbold, R., Mosimann, T., Espinola, J., Haaf, P., Thalmann, G., Moehring, B., Mueller, M., Meller, B., Reichlin, T., Murray, K., Ziller, R., Benkert, P., Osswald, S., & Mueller, C. (2013). Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J CARD FAIL, 19(12), 821-8. https://doi.org/10.1016/j.cardfail.2013.11.003

Vancouver

Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J CARD FAIL. 2013 Dez;19(12):821-8. https://doi.org/10.1016/j.cardfail.2013.11.003

Bibtex

@article{7718c1e1c9164c5abc387d41f97bfbd3,
title = "Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance",
abstract = "BACKGROUND: Biomarkers may help to monitor and tailor treatment in patients with acute heart failure (AHF).METHODS AND RESULTS: Levels of ST2, a novel biomarker integrating hypervolemic cardiac strain and proinflammatory signals, were measured at presentation to the emergency department (ED) and after 48 hours in 207 patients with AHF. Patients were stratified according to their early ST2 response (responders: ST2 decrease ≥25%; nonresponders: ST2 decrease <25%) and beta-blocker, renin-angiotensin-aldosterone system (RAAS) blockade, or diuretic treatment status at hospital discharge. We assessed the utility of ST2 levels and its changes to predict long-term mortality and the interaction between ST2 levels, treatment at discharge, and 1-year mortality. ST2 levels were higher in nonsurvivors than in survivors (median 108 vs 69 ng/mL; P < .01) and decreased significantly during the 1st 48 hours (median decrease 33%). ST2 decrease was less in nonsurvivors compared with survivors (median -25% vs -42%; P < .01). In Cox regression, early ST2 changes independently predicted 1-year mortality (hazard ratio 1.07 for every increase of 10%; P = .02). RAAS blockers at discharge were associated with survival independently from ST2 response, whereas the association of beta-blockers with survival differed markedly according to ST2 response, with beneficial effects restricted to ST2 nonresponders (P interaction = .04). A similar, albeit nonsignificant, trend was observed for diuretics (P interaction = .11).CONCLUSIONS: ED and serial ST2 measurements are independent predictors of 1-year mortality in AHF.",
keywords = "Aged, Aged, 80 and over, Biomarkers/blood, Cohort Studies, Early Diagnosis, Female, Follow-Up Studies, Heart Failure/blood, Humans, Interleukin-1 Receptor-Like 1 Protein, Male, Practice Guidelines as Topic/standards, Predictive Value of Tests, Receptors, Cell Surface/blood, Time Factors",
author = "Tobias Breidthardt and Cathrin Balmelli and Raphael Twerenbold and Tamina Mosimann and Jaqueline Espinola and Philip Haaf and Gregor Thalmann and Berit Moehring and Mira Mueller and Bernadette Meller and Tobias Reichlin and Karsten Murray and Ronny Ziller and Pascal Benkert and Stefan Osswald and Christian Mueller",
note = "Copyright {\textcopyright} 2013 Elsevier Inc. All rights reserved.",
year = "2013",
month = dec,
doi = "10.1016/j.cardfail.2013.11.003",
language = "English",
volume = "19",
pages = "821--8",
journal = "J CARD FAIL",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "12",

}

RIS

TY - JOUR

T1 - Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance

AU - Breidthardt, Tobias

AU - Balmelli, Cathrin

AU - Twerenbold, Raphael

AU - Mosimann, Tamina

AU - Espinola, Jaqueline

AU - Haaf, Philip

AU - Thalmann, Gregor

AU - Moehring, Berit

AU - Mueller, Mira

AU - Meller, Bernadette

AU - Reichlin, Tobias

AU - Murray, Karsten

AU - Ziller, Ronny

AU - Benkert, Pascal

AU - Osswald, Stefan

AU - Mueller, Christian

N1 - Copyright © 2013 Elsevier Inc. All rights reserved.

PY - 2013/12

Y1 - 2013/12

N2 - BACKGROUND: Biomarkers may help to monitor and tailor treatment in patients with acute heart failure (AHF).METHODS AND RESULTS: Levels of ST2, a novel biomarker integrating hypervolemic cardiac strain and proinflammatory signals, were measured at presentation to the emergency department (ED) and after 48 hours in 207 patients with AHF. Patients were stratified according to their early ST2 response (responders: ST2 decrease ≥25%; nonresponders: ST2 decrease <25%) and beta-blocker, renin-angiotensin-aldosterone system (RAAS) blockade, or diuretic treatment status at hospital discharge. We assessed the utility of ST2 levels and its changes to predict long-term mortality and the interaction between ST2 levels, treatment at discharge, and 1-year mortality. ST2 levels were higher in nonsurvivors than in survivors (median 108 vs 69 ng/mL; P < .01) and decreased significantly during the 1st 48 hours (median decrease 33%). ST2 decrease was less in nonsurvivors compared with survivors (median -25% vs -42%; P < .01). In Cox regression, early ST2 changes independently predicted 1-year mortality (hazard ratio 1.07 for every increase of 10%; P = .02). RAAS blockers at discharge were associated with survival independently from ST2 response, whereas the association of beta-blockers with survival differed markedly according to ST2 response, with beneficial effects restricted to ST2 nonresponders (P interaction = .04). A similar, albeit nonsignificant, trend was observed for diuretics (P interaction = .11).CONCLUSIONS: ED and serial ST2 measurements are independent predictors of 1-year mortality in AHF.

AB - BACKGROUND: Biomarkers may help to monitor and tailor treatment in patients with acute heart failure (AHF).METHODS AND RESULTS: Levels of ST2, a novel biomarker integrating hypervolemic cardiac strain and proinflammatory signals, were measured at presentation to the emergency department (ED) and after 48 hours in 207 patients with AHF. Patients were stratified according to their early ST2 response (responders: ST2 decrease ≥25%; nonresponders: ST2 decrease <25%) and beta-blocker, renin-angiotensin-aldosterone system (RAAS) blockade, or diuretic treatment status at hospital discharge. We assessed the utility of ST2 levels and its changes to predict long-term mortality and the interaction between ST2 levels, treatment at discharge, and 1-year mortality. ST2 levels were higher in nonsurvivors than in survivors (median 108 vs 69 ng/mL; P < .01) and decreased significantly during the 1st 48 hours (median decrease 33%). ST2 decrease was less in nonsurvivors compared with survivors (median -25% vs -42%; P < .01). In Cox regression, early ST2 changes independently predicted 1-year mortality (hazard ratio 1.07 for every increase of 10%; P = .02). RAAS blockers at discharge were associated with survival independently from ST2 response, whereas the association of beta-blockers with survival differed markedly according to ST2 response, with beneficial effects restricted to ST2 nonresponders (P interaction = .04). A similar, albeit nonsignificant, trend was observed for diuretics (P interaction = .11).CONCLUSIONS: ED and serial ST2 measurements are independent predictors of 1-year mortality in AHF.

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers/blood

KW - Cohort Studies

KW - Early Diagnosis

KW - Female

KW - Follow-Up Studies

KW - Heart Failure/blood

KW - Humans

KW - Interleukin-1 Receptor-Like 1 Protein

KW - Male

KW - Practice Guidelines as Topic/standards

KW - Predictive Value of Tests

KW - Receptors, Cell Surface/blood

KW - Time Factors

U2 - 10.1016/j.cardfail.2013.11.003

DO - 10.1016/j.cardfail.2013.11.003

M3 - SCORING: Journal article

C2 - 24239955

VL - 19

SP - 821

EP - 828

JO - J CARD FAIL

JF - J CARD FAIL

SN - 1071-9164

IS - 12

ER -